<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747512</url>
  </required_header>
  <id_info>
    <org_study_id>DX-CPERT-002</org_study_id>
    <nct_id>NCT01747512</nct_id>
  </id_info>
  <brief_title>An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)</brief_title>
  <official_title>A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc
      Pertechnetate in a cyclotron unit. A study done at the Cross Cancer Institute in 2011 with
      ten patients using this imaging agent showed that it was safe and produced images with the
      same pattern as generator produced Pertechnetate. This study is now being done in larger
      numbers of patients to again show that the imaging pattern of both agents is the same, and to
      again demonstrate its safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate the efficacy of cyclotron-produced Tc-99m pertechnetate (C-PERT; manufactured
      by the Edmonton PET Centre/ERC) in comparison to generator-produced Tc-99m pertechnetate
      (G-PERT; from approved commercial source; using qualitative and quantitative clinical imaging
      biodistribution data.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was not initiated
  </why_stopped>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the efficacy of C-PERT (manufactured by the Edmonton PET Centre/ERC) in comparison to G-PERT (fromm approved commercial sources) using qualitative and quantitative clinical imaging biodistribtion data.</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of C-PERT from adverse event data</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Thyroid Neoplasms</condition>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>C-PERT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>45 patients with cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-PERT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>65 patients with cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-PERT</intervention_name>
    <description>Patients with thyroid and Head and Neck cancer</description>
    <arm_group_label>C-PERT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-PERT</intervention_name>
    <description>Patients with thyroid and Head and Neck cancer</description>
    <arm_group_label>G-PERT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  thyroid cancer, or

          -  Head and Neck cancer for salivary gland transfer

          -  age 18-79

          -  biochemical parameters &lt; 5x ULN

          -  WBC &gt; 3.0/uL

          -  ANC &gt; 1.5/uL

          -  platelets &gt; 75,000/uL

          -  hemoglobin &gt; 10 g/dL

          -  Karnofsky 50-100

        Exclusion Criteria:

          -  nursing or pregnant females

          -  &lt; 18 or &gt; 79 Years

          -  uncontrolled asthma

          -  acute iritis

          -  narrow angle glaucoma

          -  previous radiation to head/neck
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander McEwan, MB, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Department of Oncology</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>99mTc Pertechnetate</keyword>
  <keyword>thyroidectomy</keyword>
  <keyword>thyroid neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Pertechnetate Tc 99m</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

